Tag: PARTNER 3
TCT 2019: TAVI has sustained health status benefits over surgery for low-risk patients at one year, with similar five-year outcomes for intermediate-risk patients, unless via a transthoracic route
A subanalysis of PARTNER 3 quality of life data demonstrated a modest, but significant, improvem...
TVT 2019: TAVI is “preferred therapy” for low-risk patients
This morning at TVT 2019 (12-15 June, Chicago, USA), in separate presentations, the principal invest...
